Allschwil, Switzerland – September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ® (daridorexant) in China. QUVIVIQ, Idorsia’s dual orexin receptor antagonist, is indicated for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep. Notably, QUVIVIQ has been approved without psychotropic drug control labeling, underscoring its differentiated clinical profile. Insomnia is a ...